INSMED INC Operating Lease, Expense
INSMED INC (INSM) reported Operating Lease, Expense of $13.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-19
- INSMED INC operating lease, expense for the quarter ending 2023-12-31 was $2.30M, a 9.52% increase year-over-year.
- INSMED INC operating lease, expense for the quarter ending 2023-09-30 was $2.60M, a 30.00% increase year-over-year.
- INSMED INC operating lease, expense for the quarter ending 2023-06-30 was $2.10M, a 10.53% increase year-over-year.
- INSMED INC operating lease, expense for the quarter ending 2023-03-31 was $2.20M, a 10.00% increase year-over-year.
- INSMED INC operating lease, expense for fiscal 2025 was $13.60M, a 14.29% increase from fiscal 2024.
- INSMED INC operating lease, expense for fiscal 2024 was $11.90M, a 29.35% increase from fiscal 2023.
- INSMED INC operating lease, expense for fiscal 2023 was $9.20M, a 15.00% increase from fiscal 2022.
- INSMED INC operating lease, expense for fiscal 2022 was $8.00M, a 63.27% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.60M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $11.90M 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.90M derived: sum of 2 quarters · filed 2026-02-19 | $7.00M derived: sum of 3 quarters · filed 2026-02-19 | $9.20M 10-K · filed 2026-02-19 |
| 2023-09-30 | $2.60M 10-Q · filed 2023-10-26 | $4.70M derived: sum of 2 quarters · filed 2023-10-26 | $6.90M 10-Q · filed 2023-10-26 | $9.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.10M 10-Q · filed 2023-08-03 | $4.30M 10-Q · filed 2023-08-03 | $6.40M derived: sum of 3 quarters · filed 2025-02-20 | $8.40M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $2.20M 10-Q · filed 2023-05-04 | $4.30M derived: sum of 2 quarters · filed 2025-02-20 | $6.30M derived: sum of 3 quarters · filed 2025-02-20 | $8.20M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.10M derived: sum of 2 quarters · filed 2025-02-20 | $6.00M derived: sum of 3 quarters · filed 2025-02-20 | $8.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | $2.00M 10-Q · filed 2023-10-26 | $3.90M derived: sum of 2 quarters · filed 2023-10-26 | $5.90M 10-Q · filed 2023-10-26 | $7.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-03 | $3.90M 10-Q · filed 2023-08-03 | $5.30M derived: sum of 3 quarters · filed 2024-02-22 | $6.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-04 | $3.40M derived: sum of 2 quarters · filed 2024-02-22 | $4.60M derived: sum of 3 quarters · filed 2024-02-22 | $5.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.60M derived: sum of 2 quarters · filed 2024-02-22 | $3.70M derived: sum of 3 quarters · filed 2024-02-22 | $4.90M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.20M 10-Q · filed 2022-10-27 | $2.30M derived: sum of 2 quarters · filed 2022-10-27 | $3.50M 10-Q · filed 2022-10-27 | $4.60M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-04 | $2.30M 10-Q · filed 2022-08-04 | $3.40M derived: sum of 3 quarters · filed 2023-02-23 | $4.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-05 | $2.30M derived: sum of 2 quarters · filed 2023-02-23 | $3.00M derived: sum of 3 quarters · filed 2023-02-23 | $4.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.80M derived: sum of 2 quarters · filed 2023-02-23 | $2.90M derived: sum of 3 quarters · filed 2023-02-23 | $3.70M 10-K · filed 2023-02-23 |
| 2020-09-30 | $700.00K 10-Q · filed 2021-10-28 | $1.80M derived: sum of 2 quarters · filed 2021-10-28 | $2.60M 10-Q · filed 2021-10-28 | $3.80M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-30 | $1.10M 10-Q · filed 2021-08-05 | $1.90M 10-Q · filed 2021-08-05 | $3.10M derived: sum of 3 quarters · filed 2022-02-17 | $3.50M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-03-31 | $800.00K 10-Q · filed 2021-05-06 | $2.00M derived: sum of 2 quarters · filed 2022-02-17 | $2.40M derived: sum of 3 quarters · filed 2022-02-17 | $3.20M derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.60M derived: sum of 2 quarters · filed 2022-02-17 | $2.40M derived: sum of 3 quarters · filed 2022-02-17 | $3.20M 10-K · filed 2022-02-17 |
| 2019-09-30 | $400.00K 10-Q · filed 2020-10-29 | $1.20M derived: sum of 2 quarters · filed 2020-10-29 | $2.00M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $800.00K 10-Q · filed 2020-08-06 | $1.60M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $800.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |